A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid Compared to Placebo in Pediatric Subjects With Biliary Atresia, Post-hepatoportoenterostomy
Latest Information Update: 25 Nov 2024
At a glance
- Drugs Obeticholic acid (Primary)
- Indications Biliary atresia
- Focus Therapeutic Use
- Sponsors Intercept Pharmaceuticals
- 19 Sep 2024 Status changed from not yet recruiting to recruiting.
- 10 Nov 2023 New trial record